Clovis Oncology Inc (OTC Pink - Limited Information:CLVSQ)

Delayed Data
As of Jun 06
 +0.0019 / +6.76%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Major

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023



Individual stakeholders3.14%
Mutual fund holders0.68%
Other institutional0.00%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial Officer & Executive Vice President
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Thomas Fuglsang HardingChief Scientific Officer & Executive VP
Paul Edward GrossSecretary, Executive VP & General Counsel